A Strategy Is Not a Holy Grail. It Is a Niche.Bitcoin / TetherUS PERPETUAL CONTRACTBINANCE:BTCUSDT.PStratVitalsA Strategy Is Not a Holy Grail. It Is a Niche. Most traders already know that backtests can fail. They know about overfitting, future leakage, survivorship bias, slippage, liquidity, and regime change. But knowing this is not the hard part. The hard part is admitting that this time, it may be your own backtest that is giving false confidence. A trading strategy is not a holy grail. It is a niche. It survives only when a specific market condition, behavioral bias, structural inefficiency, liquidity pattern, volatility regime, or risk premium remains present after costs, execution constraints, and drawdown pressure. A backtest does not prove that the niche will survive. It only shows how the strategy behaved in one historical environment. The real diagnostic questions are: What does this strategy depend on? What market condition makes it work? What can break it? Does the edge survive costs and slippage? Does it survive parameter changes? Does it survive out-of-sample data? Does it survive different regimes? Can the trader survive the drawdown path before the edge appears? This is why profit is not the diagnosis. Profit is only the outcome. The diagnosis is the evidence behind the profit. Many traders do not fail because they know nothing. They fail because they know the risk, but cannot face it when the strategy is their own. They keep optimizing when they should be questioning. They keep believing when the evidence is weakening. They call it discipline when sometimes it is only attachment. The real challenge is not building another beautiful equity curve. The real challenge is knowing whether the strategy still deserves trust. At StratVitals, our view is simple: A backtest is not proof. It is rehearsal. Profit is an outcome, not a diagnosis. A strategy is not a holy grail. It is a niche. The goal of strategy diagnosis is to find what can break a strategy before real money does. StratVitals is not a signal service, copy-trading service, trading fund, or account-management business. We do not ask traders to trust our strategy. We help them test whether they should still trust theirs. Research only. No investment advice. No trading signals.